Literature DB >> 1837566

Therapeutic response may be predicted by some clinical parameters in essential hypertensive patients.

A De la Sierra1, A Coca, J Sobrino, M M Lluch, M Sánchez, A Urbano-Márquez.   

Abstract

Several clinical parameters have been studied in a sample of 211 essential hypertensives in order to determine their usefulness as predictors of therapeutic response. One hundred and twenty-four patients (58.8%) achieved normotension with monotherapy, whereas 87 hypertensives (41.2%) needed two or more drugs to control their BP values. Patients who required a combination of drugs exhibited higher levels of systolic and diastolic BP, higher frequency of acute severe hypertension before the beginning of treatment, a more advanced stage of hypertension, and higher plasma aldosterone levels when they were compared with those controlled with a single drug. Likewise, previous cardiovascular complications related to hypertension, enlargement of cardiac silhouette on chest x-ray films and left ventricular hypertrophy were more frequent in the former. By means of a logistic regression analysis, these last three parameters showed a significant relationship with the number of required drugs. We conclude that hypertensives exhibiting this clinical profile have a higher probability of requiring a combination of drugs in the pharmacological treatment of essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1837566

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  2 in total

1.  A prospective comparison of four antihypertensive agents in daily clinical practice.

Authors:  C Campo; J Segura; M L Fernández; L Guerrero; H Christiansen; L M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2001 May-Jun       Impact factor: 3.738

Review 2.  Factors influencing the systolic blood pressure response to drug therapy.

Authors:  Carlos Campo; Julián Segura; Luis M Ruilope
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jan-Feb       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.